Article Details

Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Buy Rating from Analysts at StockNews.com

Retrieved on: 2025-05-02 10:41:49

Tags for this article:

Click the tags to see associated articles and topics

Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Buy Rating from Analysts at StockNews.com. View article details on hiswai:

Excerpt

Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 19,146 shares in the ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo